Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.

Détails

ID Serval
serval:BIB_6876CE78F3C0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.
Périodique
Antimicrobial Agents and Chemotherapy
Auteur⸱e⸱s
Marchetti O., Entenza J.M., Sanglard D., Bille J., Glauser M.P., Moreillon P.
ISSN
0066-4804 (Print)
ISSN-L
0066-4804
Statut éditorial
Publié
Date de publication
2000
Volume
44
Numéro
11
Pages
2932-2938
Langue
anglais
Résumé
Recent observations demonstrated that fluconazole plus cyclosporine (Cy) synergistically killed Candida albicans in vitro. This combination was tested in rats with C. albicans experimental endocarditis. The MICs of fluconazole and Cy for the test organism were 0.25 and >10 mg/liter, respectively. Rats were treated for 5 days with either Cy, amphotericin B, fluconazole, or fluconazole-Cy. Although used at high doses, the peak concentrations of fluconazole in the serum of rats (up to 4.5 mg/liter) were compatible with high-dose fluconazole therapy in humans. On the other hand, Cy concentrations in serum (up to 4.5 mg/liter) were greater than recommended therapeutic levels. Untreated rats demonstrated massive pseudohyphal growth in both the vegetations and the kidneys. However, only the kidneys displayed concomitant polymorphonuclear infiltration. The therapeutic results reflected this dissociation. In the vegetations, only the fungicidal fluconazole-Cy combination significantly decreased fungal densities compared to all groups, including amphotericin B (P < 0.0001). In the kidneys, all regimens except the Cy regimen were effective, but fluconazole-Cy remained superior to amphotericin B and fluconazole alone in sterilizing the organs (P < 0.0001). While the mechanism responsible for the fluconazole-Cy interaction is hypothetical, this observation opens new perspectives for fungicidal combinations between azoles and other drugs.
Mots-clé
Animals, Antifungal Agents/pharmacokinetics, Antifungal Agents/pharmacology, Candida albicans/drug effects, Candidiasis/drug therapy, Candidiasis/metabolism, Cyclosporine/pharmacokinetics, Cyclosporine/pharmacology, Disease Models, Animal, Drug Resistance, Microbial, Drug Therapy, Combination, Endocarditis/drug therapy, Endocarditis/metabolism, Female, Fluconazole/pharmacokinetics, Fluconazole/pharmacology, Kidney/drug effects, Kidney/microbiology, Microbial Sensitivity Tests, Rats, Rats, Wistar, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/01/2008 14:45
Dernière modification de la notice
20/08/2019 15:23
Données d'usage